4de Paula RB, da Silva AA, Hall JE.Aldosterone Antagonism Attenuates Obesity-Induced ltypertension and glomerular Ltyperfiltration.Hypertension.2004,43: 41～47
5Endemann DH,Touyz RM,Iglarz M,et al.Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis is stroke-prone spontaneously hypertensive rats. Hypertension.2004,43:1252～1257
6Black HR.Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin. A receptor blockers in hypertension management:A review of mechanistic and clinical data. Am Heart J 2004,147:564～572
7Funder JW.The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. Expert Opin. Investig. Drugs 2003,12(12): 1963～1969
8Thohan V, Torre-Amione G, Koemer MM.Aldosterone antagonism and congestive heart failure:a new look at an old therapy. Current Opinion in Cardiology.2004,19:301～308
9Pin, B., Remme,W., Zannad,F., Neaton, J.,Maninez.E, Roniker B.,Bittman,R., Hurley,S., Kleiman ,J., Gatlin, M.For the eplerenone post-acute myocardal infarction heart failure efficacy and survival study investigators. Eplerenone,a selective aldosterone blocker,in patients with left ventricular dysfunction afer myocardial infarction. N.Engl. J.Med.2003,348(14): 1309～1321
2Rocha R,Williams GH.Rationale for the use of aldosterone antagonists in congestive heart failure.Drugs,2002,62(5):723-731
3Hayashi M,Tsutamoto T,Wada A,et al.Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.Circulation,2003,107(20):2559-2565
4Bauersachs J,Heck M,Fraccarollo D,et al.Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction:role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.J Am Coll Cardiol,2002,39(2):351-358
5Pitt B,Zannad F,Remme WJ,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.N Engl J Med,1999,341(10):709-717
6Pitt B,Remme W,Zannad F,et al.Eplerenone,a selective aldosterone blocker,in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med,2003,348(14):1309-1321
7Cicoira M,Zanolla L,Rossi A,et al.Long-term,dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.J Am Coll Cardiol,2002,40(2):304-310
